热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
FITC anti-mouse CD69 Antibody
产品名称：
FITC anti-mouse CD69 Antibody
产品类别：
抗体
产品编号：
104505
产品应用：
104505
[价格]
规格 价格 库存
50µg ￥ 996 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda (?) light chain.

Application References

(PubMed link indicates BioLegend citation)
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Sun L, et al. 2021. Cancer Cell. :. PubMed
  2. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  3. Cordero-Reyes A, et al. 2016. J Am Heart Assoc. 5: 002484. PubMed
  4. Song Y, et al. 2020. Front Immunol. 11:558143. PubMed
  5. van Vloten JP, et al. 2022. J Immunother Cancer. 10:. PubMed
  6. Buxadé M, et al. 2018. J Exp Med. 215:2901. PubMed
  7. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  8. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  9. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  10. de Mingo Pulido , et al. 2021. Immunity. 54(6):1154-1167.e7. PubMed
  11. Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed
  12. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  13. Chen J et al. 2018. Cell reports. 25(12):3393-3404 . PubMed
  14. ?lvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed
  15. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  16. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  17. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  18. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  19. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  20. Hasezaki T, et al. 2020. Sci Rep. 10:6969. PubMed
  21. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  22. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  23. Bhattacharjee P, et al. 2018. Sci Rep. 13:e0199785. PubMed
  24. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  25. Zirngibl F, et al. 2021. J Immunother Cancer. 9:. PubMed
  26. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  27. Mandrup OA, et al. 2021. Commun Biol. 310:4. PubMed
  28. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  29. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  30. Leonard JD et al. 2017. Immunity. 47(1):107-117 . PubMed
  31. Park D, et al. 2020. Cancer Res. 80:4172. PubMed
  32. Uhde A, et al. 2016. PLoS One. 11: 0161883. PubMed
  33. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  34. Fontinha D, et al. 2015. PLoS One. 10: 0142540. PubMed
  35. Baier FA, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:745. PubMed
  36. Stanford S, et al. 2012. Proc Natl Acad Sci U S A. 109:13972. PubMed
  37. Haile S, et al. 2014. Cancer Immunol Res. 2:610. PubMed
  38. White C, et al. 2015. J Immunol. 194:697. PubMed
  39. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  40. Li C, et al. 2020. Immunity. 52(1):201-202. PubMed
  41. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  42. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  43. Lim S, et al. 2016. PLoS One. 11: 0155689. PubMed
  44. XS R, et al. 2015. Diabetes. 64 90. PubMed
  45. Moore MJ et al. 2018. eLife. 7 pii: e33057. PubMed
  46. Kang X, et al. 2022. J Immunol Res. 2022:8118577. PubMed
  47. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  48. Tao F, et al. 2013. Biochem Pharmacol. 85:798. PubMed
  49. Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
  50. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  51. Ma K, et al. 2022. iScience. 25:104347. PubMed
  52. Riva A, et al. 2017. PLoS One.. 10.1371/journal.pone.0181964. PubMed
  53. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  54. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  55. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  56. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  57. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  58. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  59. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  60. Rui J, et al. 2021. Nat Commun. 12:5074. PubMed
  61. Song TY, et al. 2021. Nat Commun. 12:7003. PubMed
  62. Klezovich-Bénard M, et al. 2012. PLoS One. 8:e1002481. PubMed
  63. Skirecki T, et al. 2020. JCI Insight. 5:. PubMed
  64. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  65. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  66. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  67. Han J, et al. 2015. Cancer Res . 75: 5273 - 5282. PubMed
  68. Kuhn NF et al. 2019. Cancer cell. 35(3):473-488 . PubMed
  69. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID
AB_313108 (BioLegend Cat. No. 104505) AB_313109 (BioLegend Cat. No. 104506)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线